Silence Therapeutics plc (SLN): Results of Operations and Financial Condition
Silence Therapeutics plc (SLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results 10 August 2026 LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and
How this was made
The 30-second read
Why it matters
Traders can use the quarter-end cash and expense trajectory to gauge runway and financing risk, while the SANRECO Phase 2 dosing completion and conference-published Phase 1/early data can influence expectations for subsequent trial readouts.
Market read
This is a primary quarterly disclosure with new cash and loss numbers plus incremental clinical progress, which can drive small-cap biotech sentiment and near-term positioning.
What to watch
Cash balance ($72.1M) and the timing of potential IND filings for earlier preclinical programs (2027) may matter more for valuation than conference presentations, which can be less predictive than trial endpoints.
Silence Therapeutics reports lower second-quarter net loss and R&D expense alongside completion of Phase 2 SANRECO patient dosing
The company materially reduced R&D expense and net loss versus the prior-year quarter, while advancing divesiran through completed Phase 2 patient dosing. However, quarterly revenue and gross profit were reported as $ —, and the filing provided no financial outlook, operating cash flow, or runway disclosure.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $ — (in thousands) | – | – |
| Cost of salesGAAP | — (in thousands) | – | – |
| Gross profitGAAP | — (in thousands) | – | – |
| Research and development costsGAAP | (9,148 ) (in thousands) | – | The $8.4 million decrease |
| General and administrative expensesGAAP | (4,717 ) (in thousands) | – | – |
| Restructuring chargesGAAP | — (in thousands) | – | – |
| Operating lossGAAP | (13,865 ) (in thousands) | – | – |
| Foreign currency gain/(loss), netGAAP | 151 (in thousands) | – | – |
| Other income, netGAAP | 669 (in thousands) | – | – |
| Benefit from R&D creditGAAP | 778 (in thousands) | – | – |
| Loss before income tax expenseGAAP | (12,267 ) (in thousands) | – | – |
| Income tax expenseGAAP | (1 ) (in thousands) | – | – |
| Net LossGAAP | $ (12,268 ) (in thousands) | – | – |
| Loss per share (basic and diluted)GAAP | $ (0.09 ) | – | – |
| Weighted average shares outstanding (basic and diluted)GAAP | 141,709,762 | – | – |
| Six-month revenueGAAP | $ 422 (in thousands) | – | – |
| Six-month cost of salesGAAP | (11 ) (in thousands) | – | – |
| Six-month gross profitGAAP | 411 (in thousands) | – | – |
| Six-month research and development costsGAAP | (18,270 ) (in thousands) | – | – |
| Six-month general and administrative expensesGAAP | (11,743 ) (in thousands) | – | – |
| Six-month restructuring chargesGAAP | — (in thousands) | – | – |
| Six-month operating lossGAAP | (29,602 ) (in thousands) | – | – |
| Six-month foreign currency gain/(loss), netGAAP | (331 ) (in thousands) | – | – |
| Six-month other income, netGAAP | 1,240 (in thousands) | – | – |
| Six-month benefit from R&D creditGAAP | 1,469 (in thousands) | – | – |
| Six-month loss before income tax expenseGAAP | (27,224 ) (in thousands) | – | – |
| Six-month income tax expenseGAAP | (1 ) (in thousands) | – | – |
| Six-month net lossGAAP | $ (27,225 ) (in thousands) | – | – |
| Six-month loss per share (basic and diluted)GAAP | $ (0.19 ) | – | – |
| Six-month weighted average shares outstanding (basic and diluted)GAAP | 141,706,190 | – | – |
| Cash and cash equivalentsGAAP | $ 72,054 (in thousands) | – | – |
| Total outstanding sharesother | 141,739,180 ordinary shares (including shares in the form of American Depositary Shares) | – | – |
What drove it
- The $8.4 million decrease in R&D expense was mainly due to zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel costs.
- The company completed patient dosing in the Phase 2 SANRECO double-blind, placebo-controlled trial evaluating divesiran 6 mg/kg at Q6W and Q12W dosing intervals in 48 phlebotomy-dependent PV patients in June 2026.
- AstraZeneca presented Phase 1 SLN312 (AZD1705) results that demonstrated a favorable safety profile and dose-dependent, durable reductions in ANGPTL3 protein levels and atherogenic lipoproteins including LDL-C, Apo-B and non-HDL-C.
- The company generated additional preclinical data for SLN365 and SLN098 and stated that each program is well positioned for a potential IND filing in 2027.
Concerns
- Quarterly revenue and gross profit were reported as $ —.
- The company remained loss-making, reporting a net loss of $ (12,268 ) (in thousands).
- The filing identified the company’s history of net operating losses and its ability to obtain necessary capital to fund clinical programs among risks.
- The filing did not provide financial guidance, cash runway, operating cash flow, free cash flow, or debt disclosure.
What to watch
- Anticipated timing of initial topline and future results from the SANRECO Phase 2 trial.
- Development progress for divesiran following completion of patient dosing in June 2026.
- Potential IND filings in 2027 for SLN365 (GPR146) and SLN098 (INHBE).
- Further development under the AstraZeneca collaboration for SLN312 (AZD1705).
Balance sheet and cash flow
- Cash and cash equivalents were $ 72,054 (in thousands) as of June 30, 2026, compared to $ 11,277 (in thousands) as of December 31, 2025.
- Short-term investments were — (in thousands) as of June 30, 2026, compared to 73,837 (in thousands) as of December 31, 2025.
- R&D benefit receivable was 9,292 (in thousands) as of June 30, 2026, compared to 22,007 (in thousands) as of December 31, 2025.
- Total current assets were 94,281 (in thousands) as of June 30, 2026, compared to 118,658 (in thousands) as of December 31, 2025.
- Total assets were $ 106,412 (in thousands) as of June 30, 2026, compared to $ 131,442 (in thousands) as of December 31, 2025.
- Total current liabilities were (12,714 ) (in thousands) as of June 30, 2026, compared to (13,613 ) (in thousands) as of December 31, 2025.
- Total liabilities were $ (67,941 ) (in thousands) as of June 30, 2026, compared to $ (69,138 ) (in thousands) as of December 31, 2025.
- Total shareholders’ equity was (38,471 ) (in thousands) as of June 30, 2026, compared to (62,304 ) (in thousands) as of December 31, 2025.
Analysis
Silence Therapeutics reported a materially smaller second-quarter loss, with net loss of $ (12,268 ) (in thousands), compared with $ (27,354 ) (in thousands) in the prior-year period. The improvement was led by research and development costs of (9,148 ) (in thousands), versus (17,647 ) (in thousands), which the company attributed mainly to completion of zerlasiran Phase 3 readiness in 2025 and reduced personnel costs. Operating loss was (13,865 ) (in thousands), compared with (23,963 ) (in thousands).
Revenue was reported as $ — (in thousands) for the quarter, compared with $ 224 (in thousands) a year earlier, and gross profit was also reported as — (in thousands). As a result, the quarterly result was primarily determined by operating spending, foreign currency gain/(loss), other income, and the benefit from R&D credit rather than recurring revenue growth. For the six months ended June 30, 2026, revenue was $ 422 (in thousands) and net loss was $ (27,225 ) (in thousands).
Pipeline execution was the central operating development. The company completed dosing in the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent PV patients during June 2026. It also presented follow-up Phase 1 SANRECO data at EHA 2026, while AstraZeneca presented Phase 1 SLN312 results describing a favorable safety profile and dose-dependent, durable reductions in ANGPTL3 protein levels and atherogenic lipoproteins.
Liquidity was $ 72,054 (in thousands) of cash and cash equivalents at June 30, 2026, while short-term investments were reported as — (in thousands), compared with 73,837 (in thousands) at December 31, 2025. The filing did not provide an operating cash flow statement, free cash flow, debt figure, cash runway, or financial guidance. The next disclosed development markers are anticipated SANRECO Phase 2 results and potential IND filings in 2027 for SLN365 and SLN098.
Not in the filing
stated, not guessed- Gross margin was not reported.
- Non-GAAP revenue, earnings, EPS, margins, or cash flow measures were not reported.
- Prior-quarter comparisons were not reported for quarterly operating metrics.
- Segment revenue and segment-level profitability were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt was not reported.
- Capital returns, including share repurchases and dividends, were not reported.
- Financial guidance for revenue, gross margin, operating expenses, or tax rate was not reported.
- Cash runway was not reported.
- Named executive commentary and named-executive quotes were not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is an SEC Form 8-K (Item 2.02) attaching a press release with Q2 2026 financial statements and business highlights for Silence Therapeutics’ siRNA pipeline.
Ticker impact
Silence Therapeutics reports Q2 2026 cash of $72.1M, R&D of $9.1M, and net loss of $12.3M, plus SANRECO dosing completion and Phase 1 updates.
Near-term volatility possible, with sentiment likely driven more by clinical read-through (SANRECO progress, Phase 1 AZD1705 data) than by the loss figures alone.
This is a primary SEC filing with new quarter-end balance sheet and updated trial milestones, but it does not include topline efficacy results or explicit guidance that would directly re-rate valuation immediately.
Market effects
Adds incremental datapoints for siRNA clinical-stage peers, reinforcing ongoing investor focus on dosing durability and pipeline progression.
Limited direct regional spillover; primarily impacts US-listed biotech sentiment and small-cap biotech risk appetite.
Modest global relevance, as the disclosure is company-specific and does not signal a broader regulatory or platform-wide shift.
Counterpoint
The financials show continued cash burn and net losses, so the clinical updates may not translate into near-term de-risking without topline efficacy or regulatory milestones.
Key entities
- companySilence Therapeutics plc
Nasdaq-listed clinical-stage siRNA developer reporting Q2 2026 financial results and pipeline milestones.
- programdivesiran (TMPRSS6)
Lead siRNA candidate for polycythemia vera; Phase 1 SANRECO follow-up data presented and Phase 2 dosing completed.
- programSLN312 (AZD1705, ANGPTL3)
siRNA candidate for dyslipidemia; Phase 1 results presented by AstraZeneca with safety and protein reduction data.
